Cumberland Partners Ltd Raises Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Cumberland Partners Ltd grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 4.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,660 shares of the medical research company’s stock after buying an additional 65 shares during the period. Cumberland Partners Ltd’s holdings in IQVIA were worth $393,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Versant Capital Management Inc lifted its position in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares during the period. Opal Wealth Advisors LLC acquired a new stake in shares of IQVIA during the second quarter worth about $27,000. Capital Performance Advisors LLP purchased a new stake in IQVIA in the third quarter valued at approximately $27,000. Park Place Capital Corp acquired a new position in IQVIA in the 3rd quarter worth approximately $28,000. Finally, Itau Unibanco Holding S.A. purchased a new position in IQVIA during the 2nd quarter worth approximately $29,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.60% of the stock is owned by company insiders.

IQVIA Trading Down 1.6 %

IQV stock opened at $213.57 on Wednesday. The stock has a market cap of $38.76 billion, a price-to-earnings ratio of 28.03, a PEG ratio of 2.23 and a beta of 1.51. The business’s 50-day moving average is $230.31 and its 200 day moving average is $229.04. IQVIA Holdings Inc. has a 12-month low of $191.45 and a 12-month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of research reports. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Morgan Stanley reduced their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. The Goldman Sachs Group lowered their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. TD Cowen decreased their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Argus raised shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $259.13.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.